Possible	0	8	O
role	9	13	O
of	14	16	O
cyclooxygenase	17	31	B-Gene_or_gene_product
II	32	34	I-Gene_or_gene_product
in	35	37	O
the	38	41	O
acquisition	42	53	O
of	54	56	O
ovarian	57	64	B-Multi-tissue_structure
luteal	65	71	I-Multi-tissue_structure
function	72	80	O
in	81	83	O
rodents	84	91	O
.	91	92	O

The	94	97	O
development	98	109	O
of	110	112	O
the	113	116	O
corpus	117	123	B-Multi-tissue_structure
luteum	124	130	I-Multi-tissue_structure
(	131	132	O
CL	132	134	B-Multi-tissue_structure
)	134	135	O
,	135	136	O
which	137	142	O
involves	143	151	O
angiogenesis	152	164	O
,	164	165	O
is	166	168	O
essential	169	178	O
for	179	182	O
the	183	186	O
establishment	187	200	O
of	201	203	O
early	204	209	O
pregnancy	210	219	O
.	219	220	O

We	221	223	O
investigated	224	236	O
the	237	240	O
roles	241	246	O
of	247	249	O
the	250	253	O
prostaglandin	254	267	B-Drug_or_compound
synthases	268	277	O
cyclooxygenase	278	292	B-Gene_or_gene_product
(	293	294	I-Gene_or_gene_product
COX	294	297	I-Gene_or_gene_product
)	297	298	I-Gene_or_gene_product
I	299	300	I-Gene_or_gene_product
and	301	304	O
COX	305	308	B-Gene_or_gene_product
-	308	309	I-Gene_or_gene_product
II	309	311	I-Gene_or_gene_product
in	312	314	O
angiogenesis	315	327	O
and	328	331	O
progesterone	332	344	B-Drug_or_compound
production	345	355	O
in	356	358	O
the	359	362	O
newly	363	368	O
formed	369	375	O
CL	376	378	B-Multi-tissue_structure
,	378	379	O
using	380	385	O
inhibitors	386	396	O
of	397	399	O
the	400	403	O
COX	404	407	B-Gene_or_gene_product
enzymes	408	415	I-Gene_or_gene_product
and	416	419	O
the	420	423	O
gonadotropin	424	436	B-Gene_or_gene_product
-	436	437	O
induced	437	444	O
pseudopregnant	445	459	O
rat	460	463	B-Organism
as	464	466	O
a	467	468	O
model	469	474	O
.	474	475	O

Injection	476	485	O
of	486	488	O
indomethacin	489	501	B-Drug_or_compound
,	501	502	O
a	503	504	O
nonselective	505	517	O
COX	518	521	B-Gene_or_gene_product
inhibitor	522	531	O
,	531	532	O
on	533	535	O
the	536	539	O
day	540	543	O
of	544	546	O
ovulation	547	556	O
and	557	560	O
the	561	564	O
following	565	574	O
day	575	578	O
decreased	579	588	O
serum	589	594	B-Organism_substance
levels	595	601	O
of	602	604	O
progesterone	605	617	B-Drug_or_compound
,	617	618	O
as	619	621	O
did	622	625	O
injection	626	635	O
of	636	638	O
the	639	642	O
selective	643	652	O
COX	653	656	B-Gene_or_gene_product
-	656	657	I-Gene_or_gene_product
II	657	659	I-Gene_or_gene_product
inhibitor	660	669	O
NS	670	672	B-Drug_or_compound
-	672	673	I-Drug_or_compound
398	673	676	I-Drug_or_compound
.	676	677	O

In	678	680	O
contrast	681	689	O
,	689	690	O
a	691	692	O
selective	693	702	O
COX	703	706	B-Gene_or_gene_product
-	706	707	I-Gene_or_gene_product
I	707	708	I-Gene_or_gene_product
inhibitor	709	718	O
,	718	719	O
SC	720	722	B-Drug_or_compound
-	722	723	I-Drug_or_compound
560	723	726	I-Drug_or_compound
,	726	727	O
had	728	731	O
no	732	734	O
effect	735	741	O
on	742	744	O
serum	745	750	B-Organism_substance
progesterone	751	763	B-Drug_or_compound
concentrations	764	778	O
.	778	779	O

None	780	784	O
of	785	787	O
the	788	791	O
inhibitors	792	802	O
had	803	806	O
any	807	810	O
effect	811	817	O
on	818	820	O
the	821	824	O
weight	825	831	O
of	832	834	O
the	835	838	O
superovulated	839	852	B-Organ
ovaries	853	860	I-Organ
or	861	863	O
on	864	866	O
the	867	870	O
synthesis	871	880	O
of	881	883	O
progesterone	884	896	B-Drug_or_compound
by	897	899	O
cultured	900	908	B-Cell
luteal	909	915	I-Cell
cells	916	921	I-Cell
.	921	922	O

To	923	925	O
determine	926	935	O
whether	936	943	O
changes	944	951	O
in	952	954	O
angiogenesis	955	967	O
are	968	971	O
responsible	972	983	O
for	984	987	O
the	988	991	O
decrease	992	1000	O
in	1001	1003	O
progesterone	1004	1016	B-Drug_or_compound
synthesis	1017	1026	O
,	1026	1027	O
we	1028	1030	O
measured	1031	1039	O
hemoglobin	1040	1050	B-Gene_or_gene_product
and	1051	1054	O
CD34	1055	1059	B-Gene_or_gene_product
levels	1060	1066	O
in	1067	1069	O
luteinized	1070	1080	O
ovaries	1081	1088	B-Organ
following	1089	1098	O
injection	1099	1108	O
of	1109	1111	O
COX	1112	1115	B-Gene_or_gene_product
inhibitors	1116	1126	O
and	1127	1130	O
measured	1131	1139	O
the	1140	1143	O
relative	1144	1152	O
frequency	1153	1162	O
of	1163	1165	O
cells	1166	1171	B-Cell
positive	1172	1180	O
for	1181	1184	O
platelet	1185	1193	B-Gene_or_gene_product
-	1193	1194	I-Gene_or_gene_product
endothelial	1194	1205	I-Gene_or_gene_product
cell	1206	1210	I-Gene_or_gene_product
adhesion	1211	1219	I-Gene_or_gene_product
molecule	1220	1228	I-Gene_or_gene_product
as	1229	1231	O
a	1232	1233	O
specific	1234	1242	O
marker	1243	1249	O
for	1250	1253	O
endothelial	1254	1265	B-Cell
cells	1266	1271	I-Cell
.	1271	1272	O

All	1273	1276	O
of	1277	1279	O
these	1280	1285	O
parameters	1286	1296	O
were	1297	1301	O
reduced	1302	1309	O
by	1310	1312	O
the	1313	1316	O
COX	1317	1320	B-Gene_or_gene_product
-	1320	1321	I-Gene_or_gene_product
II	1321	1323	I-Gene_or_gene_product
inhibitors	1324	1334	O
,	1334	1335	O
suggesting	1336	1346	O
that	1347	1351	O
changes	1352	1359	O
in	1360	1362	O
the	1363	1366	O
vasculature	1367	1378	B-Multi-tissue_structure
are	1379	1382	O
responsible	1383	1394	O
for	1395	1398	O
the	1399	1402	O
decrease	1403	1411	O
in	1412	1414	O
serum	1415	1420	B-Organism_substance
progesterone	1421	1433	B-Drug_or_compound
.	1433	1434	O

Histological	1435	1447	O
examination	1448	1459	O
of	1460	1462	O
ovarian	1463	1470	B-Organ
corrosion	1471	1480	O
casts	1481	1486	O
indicated	1487	1496	O
that	1497	1501	O
NS	1502	1504	B-Drug_or_compound
-	1504	1505	I-Drug_or_compound
398	1505	1508	I-Drug_or_compound
inhibited	1509	1518	O
the	1519	1522	O
establishment	1523	1536	O
of	1537	1539	O
luteal	1540	1546	B-Multi-tissue_structure
capillary	1547	1556	I-Multi-tissue_structure
vessels	1557	1564	I-Multi-tissue_structure
following	1565	1574	O
the	1575	1578	O
injection	1579	1588	O
of	1589	1591	O
hCG	1592	1595	B-Gene_or_gene_product
.	1595	1596	O

The	1597	1600	O
results	1601	1608	O
are	1609	1612	O
consistent	1613	1623	O
with	1624	1628	O
the	1629	1632	O
hypothesis	1633	1643	O
that	1644	1648	O
the	1649	1652	O
activity	1653	1661	O
of	1662	1664	O
COX	1665	1668	B-Gene_or_gene_product
-	1668	1669	I-Gene_or_gene_product
II	1669	1671	I-Gene_or_gene_product
is	1672	1674	O
associated	1675	1685	O
with	1686	1690	O
the	1691	1694	O
formation	1695	1704	O
of	1705	1707	O
functional	1708	1718	O
CL	1719	1721	B-Multi-tissue_structure
via	1722	1725	O
its	1726	1729	O
stimulation	1730	1741	O
of	1742	1744	O
angiogenesis	1745	1757	O
.	1757	1758	O

